Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.